The world's leading insulin manufacturer faces critical decisions as weight-loss drug demand strains production capacity.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The convenience store segment faced economic challenges in 2024 with shifting consumer preferences, consolidation, inflation ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to ...

In today’s “AARP Minute,” health benefits from weight-loss drugs that aren’t cutting pounds, plus when older adults shined at the 2025 Grammy Awards.

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Some of the best health care stocks for February 2025, based on 30-day returns, include Akero Therapeutics Inc., Guardant Health Inc., and Inari Medical Inc. The best-performing health care stocks in ...